Displaying 1 - 50 of 78 results
Released Company Title Industry Topic
06 Jan 2021
07:00 CET
VIVORYON Vivoryon Therapeutics N.V. new ISIN code 20103010 Biotechnology Change in Capital
16 Dec 2020
07:00 CET
VIVORYON Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. new Home Member State 20103010 Biotechnology Other subject
14 Dec 2020
07:00 CET
VIVORYON Vivoryon Therapeutics N.V.: Successful Relocation of Vivoryon Shares Package 20103010 Biotechnology Other subject
30 Nov 2020
07:00 CET
VIVORYON Vivoryon Therapeutics N.V.: Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V. 20103010 Biotechnology Change in Capital
26 Nov 2020
07:00 CET
VIVORYON Vivoryon Therapeutics AG: Vivoryon Therapeutics Reports Third Quarter 2020 20103010 Biotechnology Other subject
19 Nov 2020
07:00 CET
VIVORYON Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020 20103010 Biotechnology Other subject
01 Oct 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG 20103010 Biotechnology General meeting / Board Meeting
03 Sep 2020
15:09 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020 20103010 Biotechnology General meeting / Board Meeting
27 Aug 2020
19:10 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law 20103010 Biotechnology Other subject
27 Aug 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports Financial Results for H1 2020 and Provides Corporate Update 20103010 Biotechnology Commercial results
20 Aug 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] 20103010 Biotechnology Other subject
20 Aug 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020 20103010 Biotechnology Other subject
04 Aug 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Receives IND Approval for Varoglutamstat's (PQ912) Phase 2 Study in Alzheimer's Disease 20103010 Biotechnology Other subject
15 Jul 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer's Disease Study with Varoglutamstat (PQ912) 20103010 Biotechnology Trends / Analyses
26 Jun 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics Provides Update on US and EU Alzheimer's Clinical Trial Program with PQ912 20103010 Biotechnology Other subject
14 May 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports First Quarter 2020 Biotechnology Commercial results
12 May 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Postpones Annual General Meeting Biotechnology General meeting / Board Meeting
07 May 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Update on May 14, 2020 Biotechnology Other subject
29 Apr 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys Biotechnology Other subject
16 Apr 2020
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer's Disease Biotechnology Legal
26 Mar 2020
13:10 CET
DE0007921835.XAMS Correction of a release from 26/03/2020, 07:00 CET/CEST - Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results Biotechnology Commercial results
26 Mar 2020
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results Biotechnology Commercial results
19 Mar 2020
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] Biotechnology Other subject
19 Mar 2020
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its Full Year 2019 Results on March 26, 2020 Biotechnology Other subject
18 Mar 2020
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Update on Phase 2b Alzheimer's Clinical Trial, VIVIAD Biotechnology Trends / Analyses
03 Mar 2020
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics to Attend Upcoming Investor Conferences Biotechnology Meetings / events
14 Jan 2020
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development Collaboration Biotechnology News contracts
07 Jan 2020
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics to Attend 38th Annual J.P. Morgan Healthcare Conference in January 2020 Biotechnology Meetings / events
20 Dec 2019
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics is Included in AScX Index Biotechnology Other subject
28 Nov 2019
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics Reports Third Quarter 2019 Biotechnology Other subject
27 Nov 2019
12:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics attends CTAD 2019 Biotechnology Meetings / events
21 Nov 2019
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019 Biotechnology Other subject
07 Nov 2019
15:30 CET
DE0007921835.XAMS Vivoryon Therapeutics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Biotechnology Other subject
04 Nov 2019
07:00 CET
DE0007921835.XAMS Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019 Biotechnology Other subject
24 Oct 2019
09:02 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL. Biotechnology Commercial operations
08 Oct 2019
13:37 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL. Biotechnology Takeover bids
29 Aug 2019
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update Biotechnology Commercial results
22 Aug 2019
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019 Biotechnology Other subject
22 Aug 2019
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] Biotechnology Other subject
08 Jul 2019
22:01 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology Biotechnology Alliances and agreements
27 Jun 2019
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with the University of Kiel to select cancer therapy candidates from its QPCTL inhibitor portfolio Biotechnology Alliances and agreements
18 Jun 2019
07:00 CEST
DE0007921835.XAMS Vivoryon Therapeutics AG: Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology Biotechnology Alliances and agreements
12 Jun 2019
07:00 CEST
DE0007921835.XAMS Probiodrug AG becomes Vivoryon Therapeutics AG Biotechnology Change in Capital
29 May 2019
18:00 CEST
DE0007921835.XAMS Probiodrug AG: Ordinary General Meeting of Shareholders of Probiodrug AG Biotechnology General meeting / Board Meeting
22 May 2019
07:00 CEST
DE0007921835.XAMS Probiodrug to attend International Conferences in June 2019 Biotechnology Other subject
16 May 2019
07:00 CEST
DE0007921835.XAMS Probiodrug AG: Probiodrug Reports First Quarter 2019 Business Update Biotechnology Commercial results
09 May 2019
07:00 CEST
DE0007921835.XAMS Probiodrug AG: Probiodrug AG to Publish its First Quarter 2019 Business Update on May 16, 2019 Biotechnology Other subject
18 Apr 2019
15:06 CEST
DE0007921835.XAMS Probiodrug AG: Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019 Biotechnology General meeting / Board Meeting
15 Apr 2019
07:00 CEST
DE0007921835.XAMS Probiodrug AG: Probiodrug raises EUR 8.2 million in successful private placement of new shares Biotechnology Change in Capital
09 Apr 2019
18:09 CEST
DE0007921835.XAMS Probiodrug AG: Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares Biotechnology Change in Capital